Navigation Links
US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
Date:7/17/2013

London, UK (PRWEB) July 17, 2013

Dermatophytic onychomycosis (DO) is one of the most widespread fungal nail infections. It is not considered to be a life-threatening disease, but it can cause considerable pain and discomfort. At present, DO therapies consist of generics which are quite effective but are not as safe as their brand-name counterparts.

New topical DO therapies are predicted to be introduced in the offing, and they are likely to scale up the total drug treatment rates in the US owing to increasing physicians’ awareness of safer and more effective treatment options. Meanwhile, given their advantages such as a shorter duration of treatment, generic therapies represent a challenge to the development of the innovative therapies.

Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 146
Price:    US$ 4,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/dermatophytic-onychomycosis-do-us-drug-forecast-n-market-analysis-to-2022.html

The report provides in-depth insights into the US DO market. It uncovers vital general information on DO including its epidemiology, key symptoms and disease treatment; and also discloses historical and present data on the DO market revenues, annual thera
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015 Forskare kan ... på  http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet ... hålls i Wien .  ... internationella forskare och vetenskapsmän som genomfördes av ... största utmaningar bristen på incitament för att ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... indtil den 22. september 2015 på  http://www.openinnovationinscience.at ... in Science", der finder sted i ... en nylig undersøgelse af internationale forskere og ... er de to største udfordringer for sundhedsvidenskaben ...
(Date:7/2/2015)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today announced a litigation update. In ... Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in the ... Virginia , the Court issued a ... claims in favor of the Defendants on the one ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... Calif., Jan. 12 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... have successfully demonstrated the,performance of the company,s ... of the platform,s ongoing alpha testing program. ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and manufacturer of the patented anti-cancer biotech product,Endu ... preliminary revenue,and earnings for the full year of ... preliminary data for the fourth quarter, Simcere expects ...
... PHOENIX, Jan. 9 Houlihan Smith & Co., ... non-control equity investment,into Sottera, Inc. d/b/a NJOY, as ... Chairman of Houlihan Smith & Company, Inc. ... Reginald McGaugh.,Terms were not disclosed. , ...
Cached Biology Technology:WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... is the world,s largest chemical company. At its headquarters ... two steam crackers, two gas and steam turbine power ... helping make information and data on every plant on ... assembly coordinators, safety experts and asset managers. A virtual ...
... 2, 2012) A Central African protected area that straddles ... been named a World Heritage Site by the United Nations ... Called ... acronym TNS) the site consists of a 25,000 km2 (10,000 ...
... but the prevalence of heart disease in pregnant mothers has ... until they are older. These women, who are generally less ... cholesterol levels and are at greater risk of heart disease ... the heart typically functions better during pregnancy due to a ...
Cached Biology News:Virtual plant planning, retrofitting and maintenance 2UN protects 'wild heart' of Central Africa 2UN protects 'wild heart' of Central Africa 3UCLA study looks at why heart attacks cause so much more damage in late pregnancy 2